Cetuximab for the Treatment of Colorectal Cancer
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cetuximab, an IgG1 chimeric monoclonal antibody against epidermal growth factor receptor (EGFR), has activity against colorectal cancers that express EGFR. METHODS: From December 2003 to August 2005, 572 patients who had colorectal cancer expressing immunohistochemically detectable EGFR and who had been previously treated with a fluoropyrimidine, irinotecan, and oxaliplatin or had contraindications to treatment with these drugs underwent randomization to an initial dose of 400 mg of cetuximab per square meter of body-surface area followed by a weekly infusion of 250 mg per square meter plus best supportive care (287 patients) or best supportive care alone (285 patients). The primary end point was overall survival. RESULTS: In comparison with best supportive care alone, cetuximab treatment was associated with a significant improvement in overall survival (hazard ratio for death, 0.77; 95% confidence interval [CI], 0.64 to 0.92; P=0.005) and in progression-free survival (hazard ratio for disease progression or death, 0.68; 95% CI, 0.57 to 0.80; P<0.001). These benefits were robust after adjustment in a multivariable Cox proportional-hazards model. The median overall survival was 6.1 months in the cetuximab group and 4.6 months in the group assigned to supportive care alone. Partial responses occurred in 23 patients (8.0%) in the cetuximab group but in none in the group assigned to supportive care alone (P<0.001); the disease was stable in an additional 31.4% of patients assigned to cetuximab and in 10.9% of patients assigned to supportive care alone (P<0.001). Quality of life was better preserved in the cetuximab group, with less deterioration in physical function and global health status scores (both P<0.05). Cetuximab treatment was associated with a characteristic rash; a rash of grade 2 or higher was strongly associated with improved survival (hazard ratio for death, 0.33; 95% CI, 0.22 to 0.50; P<0.001). The incidence of any adverse event of grade 3 or higher was 78.5% in the cetuximab group and 59.1% in the group assigned to supportive care alone (P<0.001). CONCLUSIONS: Cetuximab improves overall survival and progression-free survival and preserves quality-of-life measures in patients with colorectal cancer in whom other treatments have failed. (ClinicalTrials.gov number, NCT00079066 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cetuximab is a chimeric (mouse/human) monoclonal IgG1 antibody developed to bind the extracellular EGFR domain that blocks dimerization and ligand-induced signaling of the EGFR pathway [14].”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [14]
In the citing paper
“Patients who received cetuximab had a 6.1-month median survival compared with 4.6 months among individuals in the best supportive care group.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [14]
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Self-citationGoldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Pitot, H. C., & Alberts, S. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,249
Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
The EGF receptor family as targets for cancer therapy
Mendelsohn, J., & Baselga, J. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,340
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259
Research works printed but not linked: 3
- Mellstedt H, 2003, Drugs Today (Barc), 39, 1
- Eng C, 2007, J Clin Oncol, 25, 18s
- Van Cutsem E, 2007, J Clin Oncol, 25, 18s
Cited by
Items 801–900 of 1,001
Aparo, S., & Goel, S. (2011) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.08.006 · Cited by 26
Lemmens, V. E. P. P., de Haan, N., Rutten, H. J. T., Martijn, H., Loosveld, O. J. L., Roumen, R. M. H., & Creemers, G. J. M. (2011) · Clinical & Experimental Metastasis · doi:10.1007/s10585-010-9370-8 · Cited by 24
The application of mass‐spectrometry‐based protein biomarker discovery to theragnostics
Street, J. M., & Dear, J. W. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03610.x · Cited by 31
Iwamoto, S., Hazama, S., Kato, T., Miyake, Y., Fukunaga, M., Matsuda, C., Bando, H., Sakamoto, J., Oba, K., & Mishima, H. (2014) · PubMed · Cited by 25
Tourneau, C. L., Paolettí, X., Coquan, E., Sablin, M., Zoubir, M., & Tannock, I. F. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.5518 · Cited by 22
The Response of Cancers to BRAF Inhibition Underscores the Importance of Cancer Systems Biology
Stites, E. C. (2012) · Science Signaling · doi:10.1126/scisignal.2003354 · Cited by 22
Marks, E. I., Tan, C. R. C., Zhang, J., Zhou, L., Yang, Z., Scicchitano, A., & El‐Deiry, W. S. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1113355 · Cited by 22
Takahashi, N., Iwasa, S., Taniguchi, H., Sasaki, Y., Shoji, H., Honma, Y., Takashima, A., Okita, N. T., Kato, K., Hamaguchi, T., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.74 · Cited by 26
Martínez, M. C. R., Berry, S. R., Ko, Y., Mittmann, N., Giotis, A., Lien, K., Wong, W. W. L., & Chan, K. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2015.008730 · Cited by 27
Self-citationHaraguchi, N., Ohara, N., Koseki, J., Takahashi, H., Nishimura, J., Hata, T., Mizushima, T., Yamamoto, H., Ishii, H., Doki, Y., et al. (2016) · Molecular and Clinical Oncology · doi:10.3892/mco.2016.1088 · Cited by 25
Colorectal cancer genomics and designing rational trials
Mondaca, S., & Yaeger, R. D. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.03.27 · Cited by 23
Recent Advances Relating to the Clinical Application of Naked Monoclonal Antibodies in Solid Tumors
Argyriou, A. A., & Kalofonos, H. P. (2009) · Molecular Medicine · doi:10.2119/molmed.2009.00007 · Cited by 24
Correlation between KRAS mutation and 18F-FDG uptake in stage IV colorectal cancer
Cho, A. E.-H., Jo, K., Hwang, S. H., Lee, N., Jung, M., Yun, M., & Hwang, H. S. (2017) · Abdominal Radiology · doi:10.1007/s00261-017-1054-2 · Cited by 22
Stahler, A., Heinemann, V., Ricard, I., von Einem, J. C., Giessen-Jung, C., Westphalen, C. B., Michl, M., Heinrich, K., Miller-Phillips, L., Jelas, I., et al. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03290-y · Cited by 21
Targeting metastatic colorectal cancer – present and emerging treatment options
Berlin, J. D., & Ciombor, K. K. (2014) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s47582 · Cited by 24
Liu, J., Xie, L., Cheng, L., Qian, X., Liu, B., Hu, J. Y., Ren, W., & Yang, M. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s86966 · Cited by 23
HER2 and HER3 as Therapeutic Targets in Head and Neck Cancer
Saddawi‐Konefka, R., Schokrpur, S., Lui, A. J., & Gutkind, J. S. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000622 · Cited by 22
Clonal evolution and expansion associated with therapy resistance and relapse of colorectal cancer
Anupriya, S., Chakraborty, A., & Patnaik, S. (2022) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2022.108445 · Cited by 26
Liu, X., Tian, X., Hao, X., Zhang, H., Wang, K., Wei, Z., Wei, X., Li, Y., & Sui, J. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.11.001 · Cited by 22
Macharia, J. M., Zhang, L., Mwangi, R. W., Rozmann, N., Káposztás, Z., Varjas, T., Sugár, M., Alfatafta, H., Pintér, M., & Raposa, B. L. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02798-2 · Cited by 23
Management of colorectal cancer: A role for genetics in prevention and treatment?
Sengupta, N., Gill, K., MacFie, T. S., Lai, C. S. L., Suraweera, N., McDonald, S., & Silver, A. R. (2008) · Pathology - Research and Practice · doi:10.1016/j.prp.2008.03.003 · Cited by 23
Systemic Treatment of Gastrointestinal Cancer in Elderly Patients
Leo, S., Accettura, C., Gnoni, A., Licchetta, A., Giampaglia, M., Mauro, A., Saracino, V., & Carr, B. I. (2012) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-012-9447-5 · Cited by 27
Phua, L. C., Ng, H. W., Yeo, A. H. L., Chen, E., Lo, M., Cheah, P. Y., Chan, E. C. Y., Koh, P. K., & Ho, H. K. (2015) · Oncology Letters · doi:10.3892/ol.2015.3560 · Cited by 23
Integration of Biologic Agents With Cytotoxic Chemotherapy in Metastatic Colorectal Cancer
Jain, V. K. S., Hawkes, E. A., & Cunningham, D. (2011) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2011.04.001 · Cited by 22
Palliative treatment of unresectable metastatic colorectal cancer
Fornaro, L., Masi, G., Loupakis, F., Vasile, E., & Falcone, A. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903427997 · Cited by 26
Rosati, G., Aprile, G., Cardellino, G. G., & Avallone, A. (2016) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2016.01.006 · Cited by 23
Weiss, J. M., Olson, J. G., Deal, A. M., Chera, B. S., Weissler, M. C., Murphy, B. A., Hayes, D. N., & Gilbert, J. (2016) · Cancer · doi:10.1002/cncr.29978 · Cited by 24
Qiu, H. J., Zhuang, W., Wu, T., Xin, S., Lin, C.-Z., Ruan, H.-L., Zhu, X., Huang, M., Li, J.-L., Hou, X.-Y., et al. (2017) · The Pharmacogenomics Journal · doi:10.1038/tpj.2017.40 · Cited by 21
Comprehensive benchmarking of SNV callers for highly admixed tumor data
Bohnert, R., Vivas, S., & Jansen, G. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186175 · Cited by 25
Role of Microbial Infection-Induced Inflammation in the Development of Gastrointestinal Cancers
Kouzu, K., Tsujimoto, H., Kishi, Y., Ueno, H., & Shinomiya, N. (2021) · Medicines · doi:10.3390/medicines8080045 · Cited by 22
Innovative estimation of survival using log-normal survival modelling on ACCENT database
for the ACCENT collaborative group, Chapman, J. W., O’Callaghan, C. J., Hu, N., Ding, K., Yothers, G., Catalano, P. J., Shi, Q., Gray, R. G., O'Connell, M. J., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.34 · Cited by 25
Self-citationNakahara, Moroi, Y., Takayama, K., Itoh, E., Kido‐Nakahara, M., Nakanishi, Y., & Furue, M. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s76860 · Cited by 23
KRAS mutations and subtyping in colorectal cancer in Jordanian patients
Elbjeirami, W. M., & Sughayer, M. A. (2012) · Oncology Letters · doi:10.3892/ol.2012.785 · Cited by 21
Ma, B. B. Y., Mo, F. K. F., TONG, J. H. M., Wong, C. Y., Wong, S. C. C., Ho, W. M., Wu, Ç., Lam, P. W., Chan, K.-F., Chan, T. S. K., et al. (2015) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12342 · Cited by 21
Management of locally advanced and metastatic colon cancer in elderly patients
Kurniali, P. C., Hrinczenko, B. W., & Al-Janadi, A. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i8.1910 · Cited by 21
Management of epidermal growth factor receptor inhibitor-associated rash: a systematic review
Brown, J., Su, Y., Nellesen, D., Shankar, P., & Mayo, C. (2016) · The Journal of Community and Supportive Oncology · doi:10.12788/jcso.0193 · Cited by 22
Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview
Lin, P. S., & Semrad, T. J. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7765-9_18 · Cited by 23
Piran, M., Sepahi, N., Moattari, A., Rahimi, A., & Asad, A. G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.597536 · Cited by 24
“Among the known anticancer drugs, Cetuximab is one of the popular ones, which is amonoclonal antibody against epidermal growth factor receptor (EGFR) (17).”
BackgroundInfluentialSato, T., Osumi, H., Shinozaki, E., Ooki, A., Shimozaki, K., Kamiimabeppu, D., Nakayama, I., Wakatsuki, T., Ogura, M., Takahari, D., et al. (2021) · Anticancer Research · doi:10.21873/anticanres.15186 · Cited by 20
Chitturi, K. R., Burns, E. A., Muhsen, I. N., Anand, K., & Trachtenberg, B. H. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01215-1 · Cited by 20
Vanderlaag, K. E., Wang, W., Fayadat‐Dilman, L., Wagner, J., Bald, L. N., Grein, J., & Janatpour, M. J. (2011) · International Journal of Cancer · doi:10.1002/ijc.26089 · Cited by 20
A role for maintenance therapy in managing sarcoma
Ray-Coquard, I. L., & Cesne, A. L. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.07.003 · Cited by 20
Campanella, C., Mottolese, M., Cianciulli, A. M., Torsello, A., Merola, R., Sperduti, I., Melucci, E., Conti, S., Diodoro, M. G., Zeuli, M., et al. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-36 · Cited by 20
“Jonker et al. showed that Cetuximab increased PFS and OS when compared to best supportive care (BSC) in 572 patients previously treated with chemotherapy [ 8 ].”
Siena, S., Cutsem, E. V., Li, M., Jungnelius, U., Romano, A., Beck, R. E., Bencardino, K. B., Élez, E., Prenen, H., Sanchis, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062264 · Cited by 22
Boccia, R. V., Cosgriff, T. M., Headley, D. L., Badarinath, S., & Dakhil, S. R. (2010) · Clinical Colorectal Cancer · doi:10.3816/ccc.2010.n.014 · Cited by 21
Azad, N. S., Dasari, A. N., Arcaroli, J. J., Taylor, G., Laheru, D. A., Carducci, M. A., McManus, M. C., Quackenbush, K. S., Wright, J. J., Hidalgo, M. M., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9820-z · Cited by 20
Safety profile of new anticancer drugs
Mansi, L., Thiery-Vuillemin, A., Nguyen, T., Bazán, F., Calcagno, F., Rocquain, J., Demarchi, M., Villanueva, C., Maurina, T., & Pivot, X. B. (2010) · Expert Opinion on Drug Safety · doi:10.1517/14740330903530663 · Cited by 22
Spontaneous regression of colorectal cancer metastatic to retroperitoneal lymph nodes.
Bir, A., Fora, A. A., LeVea, C., & Fakih, M. (2009) · PubMed · Cited by 21
Guarino, M. J., Schneider, C. J., Hosford, M., Brahmer, J. R., Rudin, C. M., Finckenstein, F. G., Philip-Norton, R., Lu, H., Weber, M. R., & Ettinger, D. S. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0124 · Cited by 22
Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer
Kotsakis, A. P., & Georgoulias, V. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.498581 · Cited by 21
Translating Clinical Trials into Meaningful Outcomes
LoRusso, P. M., Schnipper, L. E., Stewart, D. J., Boerner, S. A., Averbuch, S. D., & Wolf, W. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2632 · Cited by 20
Kotani, D., Shitara, K., Kawazoe, A., Fukuoka, S., Kuboki, Y., Bando, H., Okamoto, W., Kojima, T., Doi, T., Ohtsu, A., et al. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2015.11.005 · Cited by 20
Hazama, S., Maeda, H., Iwamoto, S., Kim, H. M., Takemoto, H., Kobayashi, K., Sakamoto, J., Nagata, N., Oba, K., & Mishima, H. (2016) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.07.003 · Cited by 20
Noncoding RNAs in DNA Damage Response: Opportunities for Cancer Therapeutics
Arjumand, W., Asiaf, A., & Ahmad, S. T. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7435-1_1 · Cited by 22
Half-Chain Cetuximab Nanoconjugates Allow Multitarget Therapy of Triple Negative Breast Cancer
Colombo, M., Rizzuto, M. A., Pacini, C., Pandolfi, L., Bonizzi, A., Truffi, M., Monieri, M., Catrambone, F., Giustra, M., Garbujo, S., et al. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00667 · Cited by 21
Management of advanced colorectal cancer, part 2
Cersosimo, R. J. (2013) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp110532b · Cited by 21
Kim, S., Kim, N., Kang, K., Kim, W., Won, J., & Cho, J. (2019) · Cells · doi:10.3390/cells8080878 · Cited by 21
“However, the clinical response of the cetuximab or panitumumab directed therapeutic option is achieved in only 10~20% of unselected patients [6,7].”
BackgroundErbB2 Targeted Epigenetic Modulation: Anti-tumor Efficacy of the ADC Trastuzumab-HDACi ST8176AA1
Milazzo, F. M., Vesci, L., Anastasi, A. M., Chiapparino, C., Rosi, A., Giannini, G., Taddei, M., Cini, E., Faltoni, V., Petricci, E., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01534 · Cited by 22
“Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies such as panitumumab and cetuximab as single agents showed an activity in Kras wild-type colorectal cancer but presented limited benefits (1–2 months) (35, 36).”
BackgroundEGFR and HER3 mRNA expression levels predict distant metastases in locally advanced rectal cancer
Ho-Pun-Cheung, A., Assénat, E., Mollévi, C., Bibeau, F., Boissière‐Michot, F., Cellier, D., Azria, D., Rouanet, P., Sénesse, P., Ychou, M., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25639 · Cited by 24
BEX2 promotes tumor proliferation in colorectal cancer
Hu, Y., Xiao, Q., Chen, H., He, J., Tan, Y., Liu, Y., Wang, Z., Yang, Q., Shen, X., Huang, Y., et al. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.15171 · Cited by 20
Targeted therapies for patients with germ cell tumors
Fenner, M. H., Beutel, G., & Grünwald, V. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.4.511 · Cited by 21
Lièvre, A., Artru, P., Guiu, M., Laurent‐Puig, P., Merlin, J., Sabourin, J., Viguier, J., Bastie, A., Seronde, A., & Ducreux, M. P. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.02.016 · Cited by 21
Bagheri, S., Rahban, M., Bostanian, F., Esmaeilzadeh, F., Bagherabadi, A., Zolghadri, S., & Stanek, A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030515 · Cited by 19
Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer
Woo, J., Palmisiano, N. D., Tester, W., & Leighton, J. C. (2013) · Cancer · doi:10.1002/cncr.27994 · Cited by 20
Predictive Biomarkers in the Development of Oncology Drugs: A Therapeutic Industry Perspective
Fine, B. M., & Amler, L. C. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.9 · Cited by 19
Activation of signal pathways and the resistance to anti‐EGFR treatment in colorectal cancer
Chen, J., Huang, X., & Katsifis, A. G. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22905 · Cited by 20
Yonesaka, K., Takegawa, N., Satoh, T., Ueda, H., Yoshida, T., Takeda, M., Shimizu, T., Chiba, Y., Okamoto, I., Nishio, K., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143132 · Cited by 20
Liu, J., Lu, C., Zhang, F., Lv, W., & Liu, C. (2018) · Pathology - Research and Practice · doi:10.1016/j.prp.2018.07.026 · Cited by 20
Liu, F.-R., Bai, S., Feng, Q., Pan, X.-Y., Song, S., Fang, H., Cui, J., & Yang, J.-L. (2018) · BMC Cancer · doi:10.1186/s12885-018-4989-y · Cited by 19
Sobrero, A. F., Lenz, H., Eng, C., Scheithauer, W., Middleton, G., Chen, W., Esser, R., Nippgen, J., & Burris, H. A. (2020) · The Oncologist · doi:10.1002/onco.13591 · Cited by 22
Andersen, M. H., Dueland, S., Hagness, M., Vidnes, T. K., Finstad, E. D., Wahl, A. K., & Foss, A. E. (2012) · Scandinavian Journal of Caring Sciences · doi:10.1111/j.1471-6712.2012.00984.x · Cited by 19
Outcome after repeat resection of liver metastases from colorectal cancer
Neeff, H. P., Drognitz, O., Holzner, P. A., Klock, A., Bronsert, P., Hopt, U. T., & Makowiec, F. (2013) · International Journal of Colorectal Disease · doi:10.1007/s00384-013-1670-4 · Cited by 19
Zhang, D., Ye, J., Xu, T., & Xiong, B. (2013) · Journal of Chemotherapy · doi:10.1179/1973947813y.0000000070 · Cited by 20
Treatment patterns and metastasectomy among mCRC patients receiving chemotherapy and biologics
Song, X., Zhao, Z., Barber, B., Gregory, C. W., Wang, P. F., & Long, S. R. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.536912 · Cited by 19
Kogawa, T., Doi, A., Shimokawa, M., Fouad, T. M., Osuga, T., Tamura, F., Mizushima, T., Kimura, T., Abe, S., Ihara, H., et al. (2014) · Targeted Oncology · doi:10.1007/s11523-014-0322-0 · Cited by 20
A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer
Ferrarotto, R., Machado, K. K., Mak, M. P., Shah, N. N., Takahashi, T. K., Costa, F. P., Overman, M. J., Kopetz, S., & Hoff, P. M. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.01.008 · Cited by 19
Baas, J. M., Krens, L. L., Bos, M. M. E. M., Portielje, J. E. A., Batman, E., van Wezel, T., Morreau, H., Guchelaar, H., & Gelderblom, H. A. J. (2015) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000255 · Cited by 21
Monoclonal Antibody Therapy for Cancer
Rader, C. M. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-980-2_3 · Cited by 19
Management of Colorectal Cancer in Older Adults
Hubbard, J. M. (2015) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2015.08.002 · Cited by 19
Joerger, M., Matter-Walstra, K. W., Früh, M., Kühnel, U., Szucs, T. D., Pestalozzi, B. C., & Schwenkglenks, M. M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq431 · Cited by 18
Chen, C. T., Bartolomeo, M. D., Corallo, S., Strickler, J. H., & Goyal, L. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280871 · Cited by 20
Targeted therapies in colorectal cancer: surgical considerations.
Luu, C., Arrington, A. K., Schoellhammer, H. F., Singh, G. P., & Kim, J. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2078-6891.2013.032 · Cited by 19
Abdelwahab, S., Azmy, A., Abdelaziz, H. E., Salim, H., & Mahmoud, A. A. (2012) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1229-8 · Cited by 20
Fujii, S., Uryu, H., Akashi, K., Suzuki, K., Yamazaki, M., Tahara, M., Hayashi, R., & Ochiai, A. (2012) · International Journal of Clinical Oncology · doi:10.1007/s10147-012-0402-z · Cited by 19
“17) demonstrated improvement of overall survival (OS) in patients receiving cetuximab plus best supportive care compared with best supportive care alone [11].”
BackgroundGill, S., Dowden, S. D., Colwell, B., Collins, L. L., & Berry, S. R. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.10.002 · Cited by 20
Self-citationEllis, P. G., O’Neil, B. H., Earle, M. F., McCutcheon, S., Benson, H., Krebs, M., Lokay, K., & Barry, A. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2016.019232 · Cited by 19
Gouverneur, A., Claraz, P., Rousset, M., Arnaud, M., Fourrier‐Réglat, A., Pariente, A., Aparicio, T., Miremont‐Salamé, G., & Noïze, P. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0529-y · Cited by 22
“Moreover, dermatitis acneiform, skin rash and rash severity, in particular grade 2 or higher, would be related to the effectiveness of the treatment [19, 32, 33].”
BackgroundToward a Tiered Model to Share Clinical Trial Data and Samples in Precision Oncology
Broes, S., Lacombe, D. A., Verlinden, M., & Huys, I. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00006 · Cited by 20
Oxaliplatin rechallenge in metastatic colorectal cancer patients after prior oxaliplatin treatment
Kim, J., Kang, J., Hong, Y. S., Kim, K., Kim, T. W., Kim, T. W., & Kim, J. E. (2018) · Medical Oncology · doi:10.1007/s12032-018-1124-5 · Cited by 18
Peng, Z., Hou, X., Huang, Y., Xie, T., & Hua, X. (2020) · BMC Cancer · doi:10.1186/s12885-020-07486-w · Cited by 19
Saif, M. W. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s264156 · Cited by 21
Lungulescu, C. V., Ungureanu, B. S., Turcu-Ştiolică, A., Ghimpău, V., Artene, Ş.-A., Cazacu, I. M., Grecu, A. F., Dinescu, V. C., Croitoru, A. E., & Volovăț, S. R. (2020) · Scientific Reports · doi:10.1038/s41598-020-78497-7 · Cited by 19
PharmGKB summary: very important pharmacogene information for the epidermal growth factor receptor
Hodoğlugil, U., Whirl‐Carrillo, M., Hebert, J. M., Karachaliou, N., Rosell, R., Altman, R. B., & Klein, T. E. (2013) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283655091 · Cited by 19
Xu, Y., Methuku, N. K., Coimbatore, P., Fitzgerald, T. F., Huang, Y., Xiao, Y.-Y., Pagala, M. K. D., Gupta, S., Solomon, W. B., Rubin, P., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0220 · Cited by 18
Gene editing particle system as a therapeutic approach for drug-resistant colorectal cancer
Ryu, J., Choi, Y. J., Won, E.-J., Hui, E., Kim, H., Cho, Y., & Yoon, T. (2020) · Nano Research · doi:10.1007/s12274-020-2773-1 · Cited by 20
Subbiah, V., Dumbrava, E. I., Jiang, Y., Thein, K. Z., Naing, A., Hong, D. S., Fu, S., Piha-Paul, S. A., Tsimberidou, A. M., Jankú, F., et al. (2020) · Experimental Hematology and Oncology · doi:10.1186/s40164-020-00159-1 · Cited by 20
Emerging profile of cetuximab in non-small cell lung cancer
Ettinger, D. S. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.07.012 · Cited by 18
Current situation of zalutumumab
Rivera, F., Salcedo, M., Vega, N., Blanco, Y., & López, C. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590902932871 · Cited by 19
Setting Future Standards for KRAS Testing in Colorectal Cancer
van Krieken, J. H., & Tol, J. (2008) · Pharmacogenomics · doi:10.2217/14622416.10.1.1 · Cited by 20
Melichar, B., Casado, E., Bridgewater, J. A., Bennouna, J., Campone, M., Vítek, P., Delord, J., Cerman, J., Salazar, R., Dvořák, J., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.438 · Cited by 17
Metadata
- Authors
- Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., Tebbutt, N. C., van Hazel, G., Wierzbicki, R., Langer, C., & Moore, M. J.
- Affiliations
- University of Ottawa (CA)
- Flinders Medical Centre (AU)
- The University of Melbourne (AU)
- Queen's University (CA)
- Cross Cancer Institute (CA)
- Sunnybrook Health Science Centre (CA)
- St. Boniface Hospital (CA)
- Queen Elizabeth Hospital (AU)
- The University of Sydney (AU)
- Austin Health (AU)
- Lakeridge Health (CA)
- Bristol-Myers Squibb (United States) (US)
- Princess Margaret Cancer Centre (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-15
- Volume
- 357
- Issue
- 20
- Pages
- 2040-2048
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2115790682
- Cited by
- 1,904
- References
- 20
- Citations by year
- 2026: 23 · 2025: 47 · 2024: 56 · 2023: 60 · 2022: 62 · 2021: 63 · 2020: 87 · 2019: 82 · 2018: 84 · 2017: 101 · 2016: 110 · 2015: 133 · 2014: 143 · 2013: 150 · 2012: 153
- FWCI
- 68.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- cetuximab, colorectal cancer, epidermal growth factor receptor, EGFR-positive tumors, monoclonal antibody therapy, best supportive care, overall survival, progression-free survival, rash, quality of life, adverse events, irinotecan, oxaliplatin, fluoropyrimidine
- MeSH terms
- Cetuximab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Exanthema, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Colorectal Neoplasms, Survival Analysis, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.